#### Impacts of the COVID-19 pandemic on antibiotic use and resistance in hospitals: a retrospective ecological analysis of French national surveillance data over 2019-2022

Maylis Layan<sup>1,2,3,4</sup>, David R M Smith<sup>5</sup>, Solen Kernéis<sup>6,7</sup>, Loïc Simon<sup>8</sup>, Catherine Dumartin<sup>9,10</sup>, Lory Dugravot<sup>8</sup>,

Amélie Jouzeau<sup>8</sup>, Sylvie Maugat<sup>11</sup>, Laetitia Gambotti<sup>11</sup>, Laurence Watier<sup>2,4</sup>, Lulla Opatowski<sup>2,4</sup>, Laura Temime<sup>1,3</sup><sup>‡</sup>

<sup>1</sup>PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France

9 <sup>2</sup>Epidemiology and Modelling of Antibiotic Evasion (EMAE), Institut Pasteur, Université de Paris, Paris, France

<sup>3</sup>Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France

- <sup>4</sup>CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-
- Bretonneux, France
- <sup>5</sup>Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- <sup>6</sup>Université Paris Cité, INSERM, IAME, F-75018 Paris, France
- <sup>7</sup>Equipe de Prévention du Risque Infectieux (EPRI), AP-HP, Hôpital Bichat, Paris, France
- <sup>8</sup>CPIAS Grand-Est, CHRU Nancy, France
- <sup>9</sup>CPIAS Nouvelle-Aquitaine, CHU de Bordeaux, Bordeaux, France
- <sup>10</sup>Univ. Bordeaux, INSERM, BPH, U1219, Team AHeaD, Bordeaux, France
- <sup>11</sup>French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France
- <sup>‡</sup>Contributed equally

#### **Corresponding author:**

- Maylis Layan (m.layan@hotmail.fr)

Keywords: antibiotic resistance ; antibiotic use ; hospital ; COVID-19 ; temporal dynamics ; multivariate count regression

### 47 Summary

### 48 Background

49 The COVID-19 pandemic led to major disruptions in healthcare services at the hospital and community

- 50 levels. The resulting impact on antibiotic resistance (ABR) in hospitals is difficult to predict.
- 51

### 52 Methods

- 53 We exploited data from the French national surveillance system over four years (2019-2022) including
- 54 414 hospitals across 12 French regions. We evaluated changes in annual antibiotic use compared to 2019
- using multiple comparison tests. We also compiled a large dataset of 692,551 incident isolates for five
- 56 antibiotic-bacterium pairs. Using negative binomial regression models accounting for autocorrelation and
- 57 antibiotic use, we evaluated associations between resistant isolates incidence and COVID-19 indicators
- 58 (pandemic periods or intubated COVID-19 patient prevalence). We investigated how these associations
- 59 varied specifically in ICUs (*n*=85) and across geographical regions.
- 60

### 61 Findings

The use of some antibiotics, including azithromycin, imipenem and meropenem, significantly increased between 2020 and 2022. Concomitantly, the incidence of methicillin-resistant *Staphylococcus aureus* (up to 37%, 95% CI: 18-53%) and ESBL-producing *Escherichia coli* (up to 33%, 95% CI: 16-46%) isolates significantly decreased in hospitals and ICUs during the pandemic. A transient decrease in ICUs was also observed for ESBL-producing *Klebsiella pneumoniae* during periods of strong anti-COVID-19 interventions in the community (24%, 95% CI: 6-38%). No significant changes for ESBL-producing *Enterobacter cloacae* complex were observed. Very interestingly, the incidence of carbapenem-resistant *Pseudomonas* 

- 69 *aeruginosa* isolates was associated with COVID-19 intubation prevalence in hospitals (p<0.001) and ICUs
- 70 (p<0.001), notably in the regions most affected by the pandemic.
- 71

# 72 Interpretation

- 73 Our results highlight strong modifications of antibiotic use and pathogen-specific global impacts of the
- 74 COVID-19 pandemic on ABR in hospitals. Even though the biological mechanisms underlying between-75 species differences remain unclear, these results provide important insights into the potential impacts of
- 76 a viral pandemic on ABR and support the need for pandemic preparedness in healthcare facilities.
- 77

# 78 Funding

- 79 ANR-10-LABX-62-IBEID.
- 80
- 81
- 82
- 83
- 00 Q/
- 84 85
- 86
- 87
- 88
- 89
- 09
- 90
- 91

#### 92 Research in context

#### 93 Evidence before this study

94 We searched PubMed for articles in English published between Jan 1, 2020, and August 31, 2024 exploring 95 national-scale changes in antibiotic resistance (ABR) within healthcare settings during the COVID-19 96 pandemic. Search terms for titles and abstracts were ("antibiotic resistance" OR "antimicrobial resistance" 97 OR "bacterial resistance" OR "drug resistance" OR "MRSA" OR "ESBL" OR "carbapenem resistant") AND 98 ("hospital" OR "healthcare") AND ("COVID-19" OR "SARS-CoV-2") AND ("national" OR "nationwide"). The 99 search yielded 94 results. We identified 12 relevant studies after filtering out articles referring to viruses, 100 parasites, or fungi, focusing on a single hospital, evaluating changes in antibiotic use only, assessing 101 healthcare workers' practices, or using qualitative approaches. All studies used either national 102 surveillance data on antibiotic resistance or large multi-center cohorts of inpatients. Five studies showed 103 a significant increase in MRSA, at least during the first wave of the COVID-19 pandemic, while two studies 104 did not find changes at the national level compared to 2019. Interestingly, one study showed that the 105 abandonment of infection prevention and control strategies that specifically target hospital-acquired 106 MRSA infections was associated with an increase of these infections, regardless of COVID-19 admission 107 prevalence. One study in Spain showed decreased resistance of *P. aeruginosa* to all tested antibiotics in 108 2022 compared to 2017, using point prevalence survey results. Conversely, one study focusing on US 109 Veterans Affairs hospitals showed increased incidence and resistance of healthcare-associated 110 carbapenem-resistant P. aeruginosa (CR-PA) infections during the pandemic. Most studies used univariate 111 statistical approaches. Only two studies included COVID-19-related variables in their models; they found 112 no association with MRSA or extended-spectrum cephalosporin-resistant E. coli and K. pneumoniae.

#### 113

#### 114 Added value of this study

115 Here, we provide the first evaluation of the impact of the pandemic on antibiotic consumption and 116 resistance for five antibiotic-bacterium pairs (MRSA, CR-PA, ESBL-producing E. coli, ESBL-producing K. 117 pneumoniae, and ESBL-producing *E. cloacae* complex) in hospitals, at the national and regional scales. By 118 analyzing French surveillance data from the SPARES database including 414 hospitals that represent up to 119 14% of French hospitals, we evaluated annual changes in antibiotic use and quantified the impacts at the 120 weekly level of the COVID-19 pandemic on the incidence of five of the most prevalent resistant bacteria 121 in France. Accounting for autocorrelation and antibiotic use, factors that were not considered in previous 122 studies, we report a significant positive association between the weekly incidence of CR-PA isolates and 123 the prevalence of intubated COVID-19 patients in the preceding weeks. Carbapenem use and intubation 124 being risk factors of CR-PA infections, our results suggest a direct impact of the pandemic on CR-PA 125 epidemiology. Inversely, we show that the incidence of ESBL-producing E. coli and MRSA isolates 126 decreased after the start of the first pandemic wave at the hospital level but also in ICUs. The fine grain 127 analysis across 12 French administrative regions revealed regional heterogeneities, but highlighted 128 consistent associations in the regions most affected by the COVID-19 pandemic.

129

### 130 Implications of all the available evidence

Pandemics not only destabilize healthcare systems by adding pressure and changing healthcare worker 131 132 behaviors, but also influence the epidemiology of other infectious diseases as shown in our study. We 133 specifically highlight the contrasting effects of the COVID-19 pandemic on ABR in French hospitals, 134 associated with an increase in CR-PA isolate incidence but a general decrease in ESBL-producing E. coli 135 and MRSA. This work highlights how national-scale hospital surveillance systems such as SPARES that 136 collect data at the weekly level are key to capture the evolving impacts of pandemics. They also allow to 137 generate hypotheses on the potential mechanisms of action of the pandemic on ABR epidemiology, as 138 showcased by the analysis of CR-PA isolates incidence, and thereby participate in the improvement of 139 healthcare systems in pandemic context.

# 140

141

### 142 Introduction

143

144 Antibiotic resistance (ABR) is a leading health problem worldwide associated with an estimated 1.14 (1.00-145 1.28) million deaths in 2021.<sup>1</sup> Exceptional health events, such as pandemics, lead to major changes in care 146 and hygiene practices in both the community and hospitals, which may modify ABR epidemiology. For 147 instance, during the COVID-19 pandemic, social distancing measures<sup>2</sup> and reduced outpatient antibiotic 148 prescription<sup>3,4</sup> might have reduced ABR burden in hospitals. Healthcare workers (HCWs) also reported greater hand hygiene compliance and availability of alcohol-based hand rub.<sup>5,6</sup> On the other hand, 149 150 inpatient antibiotic use increased in France,<sup>7</sup> probably related to the high proportion of COVID-19 patients receiving antibiotics as reported in several meta-analyses.<sup>8,9</sup> In parallel, surges in COVID-19 patients in 151 hospitals often exceeded bed capacity with a sicker patient-case mix.<sup>5</sup> This generated higher workload 152 153 and decreased the time that HCWs could allocate to antibiotic stewardship and infection prevention and 154 control (IPC).<sup>5</sup> A striking example is the increase of MRSA incidence in US Veterans Affairs hospitals with 155 interrupted IPC during the pandemic.<sup>10</sup> The combined impact of all these effects, at the community and 156 hospital levels, is difficult to predict<sup>11</sup> and may have changed throughout the pandemic, which was notably 157 marked by the improvement of COVID-19 patient management and treatment (e.g. reduction in antibiotic 158 prescribing<sup>12,13</sup> and mechanical ventilation<sup>14</sup>).

159

160 Several studies have attempted to quantify the impacts of the pandemic on ABR in hospitals, but the 161 evidence remains conflicting.<sup>10,15,16</sup> A meta-analysis estimated that MRSA incidence did not change during 162 the pandemic, whereas there was a statistically insignificant trend for increased incidence of extendedspectrum  $\beta$ -lactamase (ESBL)-producing Enterobacterales and CR-PA.<sup>15</sup> Heterogeneity in terms of settings, 163 164 study design, and health outcomes, as well as heterogeneity in baseline epidemiological situations and 165 local practices, might have undermined the statistical power of this meta-regression. A recent 166 comprehensive study on antibiotic-resistant healthcare-associated infections in US Veterans Affairs 167 hospitals also highlighted varying trends across antibiotic-bacterium combinations during the pandemic.<sup>16</sup>

168

169 Here, we aimed to assess the impacts of the pandemic on antibiotic use and antibiotic-resistant bacteria 170 in French hospitals using large-scale surveillance data over 2019-2022. We evaluated changes in antibiotic 171 use in hospitals compared to 2019 as a potential key mechanism of pandemic action on ABR epidemiology 172 in hospitals. For five antibiotic-resistant bacteria of major importance in French hospitals (ESBL-producing 173 E. coli - ESBL-EC, ESBL-producing K. pneumoniae - ESBL-KP, ESBL-producing E. cloacae complex - ESBL-ECC, 174 MRSA, and CR-PA), we quantified the association between their incidence and the burden of severe 175 COVID-19 patients, we investigated whether these associations were similar in the specific context of 176 intensive care units (ICUs), and we evaluated how associations with the pandemic varied across 177 geographical regions.

- 178 179
- 180 Methods
- 181
- 182 Data sources
- 183
- 184 Antibiotic resistance and antibiotic consumption in hospitals
- 185

We obtained ABR and antibiotic use data from the French National Surveillance Database on Antibiotic Resistance in hospitals (SPARES). SPARES compiles data reported by participating hospitals on (*i*) microbiological test results from clinical samples and (*ii*) annual antibiotic consumption by anatomical therapeutic chemicals (ATC) class (Figure 1A).<sup>7</sup> Consolidated data are only available from 2019 on. SPARES provided us with microbiological test results and antibiotic use data from the 1<sup>st</sup> of January 2019 to the 31<sup>st</sup> of December 2022.

192

Clinical tests reported in SPARES encompass infection and colonization events. No information about the
 source of acquisition (community or healthcare) is available. Clinical test results are interpreted according
 to the EUCAST guidelines by participating hospitals.

196

Hospitals report their annual antibiotic consumption by ATC class in number of defined daily doses (DDD)
for 1,000 bed-days.

200 Hospital stays

We obtained data on occupied bed-days from the National Hospital Discharge Database (PMSI), a database dedicated to hospital activity evaluation for budget allocation. As such, it documents for all hospital stays their type, duration, associated diagnoses and medical procedures. We exploited this database to extract the weekly number of occupied bed-days in acute care facilities between the 1<sup>st</sup> of January 2019 and the 31<sup>st</sup> of December 2022. We also extracted the weekly number of intubated COVID-19 patients' bed-days (appendix pp 6-7).

208

#### 209 **Data selection procedure** 210

- 211 We explored ESBL-EC, ESBL-ECC, ESBL-KP, MRSA, and CR-PA dynamics since they are on the WHO priority 212 list<sup>17</sup> and amongst the resistant bacteria with highest incidence in France.<sup>18</sup> Of all available isolates in 213 SPARES (n=2,370,650), we selected the ones corresponding to the studied bacterial species that are tested 214 for the resistance of interest. Importantly, when multiple samples potentially corresponded to the same 215 acquisition episode and were performed within a 30-day period, we kept only the first sample as we were interested in incident episodes (Figure 1B). Our selection procedure led to the inclusion of 692,551 216 217 episodes, 74,387 of which were resistant. Concerning antibiotics, only ATC-J01 antibiotics reported over 218 the four years of the study period were included (appendix pp 2-3).
- 219

Hospitals report their data to SPARES on a voluntary basis leading to non-exhaustive and possibly non representative data collection. To ensure our analysis is based on a temporally stable database, we restricted our analyses to hospitals that systematically reported their antibiotic consumption and clinical tests results over the four years of the study period. Other exclusion criteria are listed in Figure 1C. Selected hospitals (*n*=414) are distributed over the 12 administrative regions of hexagonal France (Figure 1D). We assessed the representativeness of our cohort in appendix pp 3-6.

### 227 Outcomes

We investigated the dynamics of the following outcomes at the national and/or regional levels and at the
hospital and/or ICU levels over the study period:

Annual proportion of resistant episodes for each antibiotic-bacterium pair: annual number of
 resistant episodes divided by annual number of total episodes.

- Weekly incidence of resistant bacterial isolates: weekly number of incident resistant episodes
   divided by weekly number of occupied bed-days (from the PMSI) times 1,000.
  - Annual consumption of antibiotics in DDD for 1,000 bed-days.
- 235 236

238

- 237 The hospital level included rehabilitation care, general medicine, surgery, gynecology-obstetrics, and ICU.
- 239 Statistical analyses
- 240
- 241 *Antibiotic consumption dynamics* 242

For each antibiotic class, we evaluated whether its consumption had changed over the study period by comparing annual consumption distributions using Friedman tests (non-parametric alternative of the oneway ANOVA for repeated measures). We then explored the evolution of antibiotic consumption using 2019 as a reference year by performing three pairwise Wilcoxon signed-rank tests. We applied a Bonferroni correction for multiple testing, and reported adjusted p-values and 98.3% confidence intervals (CIs) to account for the correction.

- 249
- 250 Antibiotic-resistant episodes dynamics
- 251

For each antibiotic-bacterium pair, we evaluated whether there was a linear trend in the annual proportion of resistance in hospitals at the national level using the  $\chi^2$  test for trend in proportions. When resistance proportions exhibited a significant increase or decrease between 2019 and 2022, we estimated the slope of the linear trend using linear regression minimizing weighted least squares.

- Then, for each bacterium pair, we investigated ABR and COVID-19 association using multivariate count regression models. We modeled the incident number of resistant isolates of a bacterial species  $N_w$  during week w in hospitals or ICUs as a negative binomial distribution to account for overdispersion. The equations of the models are as follows:
- 261

256

262 263

- $N_w \sim NB\left(\lambda_w,\phi\right)$
- $log(\lambda_w) = \beta_0 + log\left(\frac{n_w}{1000}\right) + \beta_1 \cdot \frac{N_{w-1}}{n_{w-1}} \cdot 1000 + \beta_2 \cdot Antibiotic_y$
- 264 265

266 With  $\phi$  the overdispersion parameter,  $\beta_0$  the intercept,  $n_w$  the number of occupied bed-days at week w,  $\underline{n_w}$   $\underline{N_{w-1}} \cdot 1000$ 

 $\overline{1000}$  the occupied bed-days permillage at week w (offset),  $n_{w-1}$ 267 the incidence of resistant 268 bacterial isolates per 1,000 bed-days in the preceding week (w - 1) to account for autocorrelation, and  $Antibiotic_y$  the consumption level (in DDD for 1,000 bed-days) of the main antibiotic class targeted by 269 270 the resistance during year  $\mathcal{Y}$  that includes week w. Target antibiotic classes correspond to 271 imipenem+meropenem for P. aeruginosa, 3GC for Enterobacterales, and penicillins for S. aureus. We 272 considered antibiotic consumption as a confusion factor, and investigated its impact in a sensitivity 273 analysis (appendix pp 22-25). We compared this baseline model to 6 distinct models accounting for 274 COVID-19-related variables (appendix p10-11). These variables were either the period of the pandemic (a 275 categorical variable indicating the pre-pandemic period, the first wave and periods marked by three levels 276 of anti-COVID-19 restrictions in the community), or COVID-19 intubation prevalence. The levels of anti-277 COVID-19 restrictions in the community were based on Paireau and colleagues,<sup>2</sup> but we considered the

first wave separately as it was marked by a very specific context of care disorganization in hospitals. The prevalence of intubated COVID-19 patients (weekly number of intubated COVID-19 patients' bed-days divided by the weekly number of bed-days times 1,000) represented the burden of severe COVID-19 patients. For both COVID-19-related variables, we tested variables at week w, w - 1, and w - 2. Continuous explanatory variables (prevalence of COVID-19 intubation, antibiotic consumption, resistant isolate incidence at week w - 1) were on very different scales, so we standardized them to facilitate the comparison of regression coefficients across explanatory variables, models and bacterial species.

285

We calculated the 95% CIs for the regression coefficients using a normal approximation to the distribution of the maximum likelihood estimators. For each antibiotic-bacterium pair, we selected the model with the lowest Akaike Information Criterion (AIC). Models were fitted by maximum likelihood using the glm.nb function of the R package MASS (appendix pp 10-19).<sup>19</sup>

290

When the best model included COVID-19-related variables, we further explored how associations varied across the 12 administrative regions by fitting the model selected in the national analysis to regional hospital data separately for each region and accounting for overdispersion when necessary. We did not investigate regional ICU data alone due to the limited number of episodes and absence of ICUs in some regions (Figure 1D).

All statistical analyses were done with R, version 4.3.0. This study adheres to the Strengthening theReporting of Observational studies in Epidemiology (STROBE) reporting guideline.

300 Role of the funding source

302 The funders had no role in study design, data analysis, data interpretation, or writing of the paper.

303 304

299

301

### 305 Results

306

#### 307 Evolution of antibiotic use in hospitals during the pandemic in France 308

309 Annual antibiotic consumption strongly varied across hospitals (n=414, gray lines) of our cohort and across 310 antibiotic classes, penicillins and quinolones being the most used (appendix p20 and Table 1). Overall, a 311 median increase in total consumption of 7.5 DDD per 1,000 bed-days (98.3% CI: 2.7, 12.5) was found in 312 2020 compared to 2019 but it did not persist. For all antibiotic classes explored, significant changes in 313 annual consumption were found, with strong variations across classes (Table 1). Carbapenem 314 consumption, and more specifically imigenem and meropenem, showed a significant increase in 2020 and 315 2021, while cephalosporins increased until 2022. Interestingly, macrolide consumption significantly 316 increased only in 2020 (+1.71 DDD/1,000 bed-days, 98.3% CI: +0.9 to +2.6), while azithromycin 317 consumption significantly increased during the whole pandemic period.

318

Antibiotic use dynamics varied across regions (Figure 2A and appendix p 21). A significant increase of total antibiotic use was observed in 2020 in Île-de-France (IDF), Grand-Est (GES) and Auvergne-Rhône-Alpes (ARA). Interestingly, macrolide consumption significantly increased in four regions in 2020, especially azithromycin whose consumption increased in seven regions (Figure 2B). Importantly, the increase of azithromycin use persisted until 2022 in Hauts-de-France (HDF), Occitanie (OCC), and Provence-Alpes-Côte d'Azur (PAC).

### 325

326 In ICUs (n=85), we observed higher antibiotic consumption levels (appendix p20) and changes of larger 327 magnitude compared to the overall hospital level (Table 2). Although we did not find a significant change 328 in total antibiotic consumption in these wards, we observed a significantly increased use of carbapenems, 329 cephalosporins, and macrolides in 2020. Imigenem and meropenem consumption remained significantly 330 higher until 2022 (+12·42 DDD/1,000 bed-days, 98·3% CI: +1·9 to +22·4), while carbapenem use decreased 331 to its 2019 level in 2022. Macrolide (+17·41 DDD/1,000 bed-days, 98·3% CI: +7·7 to +28·9) and 332 azithromycin (+12.69 DDD/1,000 bed-days, 98.3% CI: +5.8 to +20.5) consumption significantly increased 333 but only during the first year of the pandemic, contrary to the hospital level. Finally, penicillin consumption 334 significantly decreased in 2020 and 2021 compared to 2019.

335

337

### 336 Contrasting impacts of the pandemic on ABR in French hospitals

Among the 692,551 included isolates, *E. coli* was the most represented bacteria in our dataset with 376,685 isolates (Figure 3A). The evolution of annual resistance rates over 2019-2022 varied across antibiotic-bacterium pairs. We found a significantly decreasing trend for MRSA (p<0.001), ESBL-EC (p<0.001), ESBL-KP (p<0.001), and ESBL-ECC (p=0.031), but a significantly increasing trend for CR-PA (p<0.001, Figures 3B-C). No clear variation of resistance proportion at the weekly level was observed (appendix p 8).

344

345 In contrast, the analysis of weekly incidence of resistant isolates revealed interesting dynamics (Figure 346 3D). Comparing regression models that included or not COVID-19-related variables at the country level 347 led to the selection of distinct models depending on the antibiotic-bacterium pair. For ESBL-EC and MRSA, 348 the selected model included the pandemic periods. For CR-PA, the prevalence of intubated COVID-19 349 patients two weeks prior was selected. Incidence significantly decreased for ESBL-EC (up to 15% decrease, 350 95% CI: 11-19%) and MRSA (up to 26% decrease, 95% CI: 22-30%) after the first pandemic wave, while the 351 prevalence of intubated COVID-19 patients was significantly associated with higher incidence of CR-PA 352 isolates (p<0.001, Figure 4A).

353

Focusing on ICUs, we observed similar patterns with slight differences (Figure 4A). Notably, MRSA isolates incidence significantly decreased from the first pandemic wave onwards (up to 37% decrease, 95% CI: 18-53%) and the best model for ESBL-KP included the pandemic periods with a significant decrease in incidence during the periods of strong anti-COVID-19 interventions (24% decrease, 95% CI: 6-38%). 358

At the regional level, we estimated that COVID-19 intubation prevalence was significantly associated with an increased incidence of CR-PA isolates in IDF (p=0.005), GES (p=0.006), ARA (p=0.008), and PAC (p=0.004, Figure 4C). Interestingly, these regions were amongst the most affected by the pandemic (Figure 4E). These results strengthen the evidence that the pandemic may have led to an increase in CR-PA isolate incidence. For ESBL-EC and MRSA, associations between incidence and pandemic periods are highly heterogeneous across administrative regions with evidence of a significant decrease in incidence after the first pandemic wave in multiple regions (Figure 4D).

366 367

### 368 Discussion

369

Using national surveillance data in French hospitals between 2019 and 2022, we showed changes in antibiotic use over the course of the pandemic, highlighting increasing use of azithromycin, imipenem,

and meropenem. We also found that the pandemic had contrasting impacts on ABR, that varied across
 antibiotic-bacterium pairs and administrative regions, which could be due to differences in the modes of
 transmission, spatiotemporal dynamics, and drivers of the five studied antibiotic-bacterium pairs. These
 differences across pairs stress that ABR should not be regarded as a one-solution problem.

376

377 We estimated overall reductions in use of penicillins in hospitals over the study period, as observed in 378 2020 in the community in France,<sup>4</sup> probably due to the reduction of common infections generally treated 379 with penicillins. They were probably replaced by cephalosporins and carbapenems for which we showed 380 an increased use. We also showed an increased use of macrolides, among which azithromycin, as 381 observed in the community.<sup>3,4</sup> These changes are certainly due to the management of COVID-19 patients, 382 at least at the start of the pandemic, when COVID-19 patients represented most of the hospitalizations. 383 Indeed, cephalosporins, carbapenems, and azithromycin were the antibiotics most commonly prescribed 384 to COVID-19 patients.<sup>8,12,13</sup> Importantly, we showed that azithromycin use in hospitals and imipenem and 385 meropenem use in ICUs remained high until 2022. These increases are concomitant with higher 386 carbapenem resistance in *P. aeruginosa* as shown here, and could have led to the increase of azithromycin 387 resistance,<sup>20</sup> or even other resistances.<sup>20</sup> Unfortunately, we could not evaluate azithromycin resistance 388 given the very limited number of bacterial isolates tested for this antibiotic. All these dynamics may have 389 changed selective pressures in hospitals and require careful attention. It is important to stress that we did 390 not assess antibiotic use dynamics in the community, which can also impact the selective pressure in 391 hospitals.

392

393 To the best of our knowledge, this is the first study evaluating the association between ABR and COVID-394 19-related variables in hospitals using weekly level national surveillance data that also include antibiotic 395 use or autocorrelation terms.<sup>10,21</sup> The results from our regression analysis suggest that CR-PA isolate 396 incidence increased with COVID-19 intubation prevalence, an association that we also quantified at the 397 regional level and that is certainly driven by ICUs (appendix p 26). We further confirmed this association 398 in a sensitivity analysis where likelihood ratio tests always selected the model with COVID-19 intubation 399 at w-2 rather than COVID-19 intubation in the following weeks (w+1, w+2, and w+3, appendix pp 26-27). These results are in agreement with previous studies.<sup>15,16,22</sup> A possible mechanism explaining 400 401 this association pertains to the increase of known risk factors of CR-PA infections, notably more frequent 402 intubation,<sup>23</sup> longer hospitalizations, and higher antibiotic use in COVID-19 patients.<sup>23,24</sup> Interestingly, 403 when we did not account for imipenem and meropenem use in the hospital regression model, the AICs of 404 the models including the pandemic periods at week w-1 or the prevalence of intubated COVID-19 405 patients at week w-2 were equivalent. Still, we estimated an increased incidence compared to the pre-406 pandemic period in the model with the pandemic periods at week w - 1 (appendix pp 22-25). 407

408 In contrast, our analysis shows that MRSA and ESBL-EC isolates incidence significantly decreased during 409 the pandemic. Previous reports have highlighted a steady decrease of MRSA incidence since 2003 in 410 France,<sup>25</sup> as well as a recent decrease of ESBL-EC between 2016 and 2018.<sup>26</sup> Thus, it is difficult to assess 411 whether the decrease that we observe is due to long-term trends only or whether the pandemic has 412 accelerated the decrease, for instance through higher adherence to hand hygiene,<sup>5</sup> a known factor of 413 MRSA prevention.<sup>27</sup> Concerning ESBL-EC, we estimated a decrease in incidence after the first wave, but 414 our regression model does not explain incidence dynamics well during the first wave (appendix p 19). 415 According to a study in French ICUs during the first wave, COVID-19 patients were more frequently co-416 infected with ESBL-EC than non-COVID-19 patients<sup>28</sup> and a meta-analysis highlighted a higher incidence 417 of ESBL-EC during the first year of the pandemic.<sup>15</sup> It is therefore possible that the impacts of the pandemic 418 on ESBL-EC changed first with conditions that favored ESBL-EC infections, later followed by conditions that 419 prevented these infections. Again, our model did not account for the community and we also cannot rule

out the contribution of the evolution of ABR in the community on these dynamics. However, there is
 scarce evidence of changes in ESBL-EC<sup>29</sup> and MRSA in the French community.

422

In parallel, our regression analysis suggests that there is transient association between COVID-19 and ESBL-KP and no association between COVID-19 and ESBL-ECC. In our sensitivity analysis, we estimated stronger changes in ESBL-KP isolate incidence at the start of the pandemic, but they did not persist and concerned only ICUs (appendix pp 18-19). This is consistent with the literature that showed an insignificant increase in the incidence of ESBL-producing Enterobacterales.<sup>15,16</sup>

428

429 Several limitations of our study should be mentioned. As in any ecological study, we quantified changes 430 using data aggregated at the national or regional level, which hides hospital heterogeneity in terms of 431 size, hospital type, local practices, or degree to which they were affected by the COVID-19 pandemic. This 432 also prevents generalization to every French hospital. Secondly, the analyses were carried out on a 433 subsample of French hospitals, representing about 14% of all French hospitals (3,008 in 2019). While this 434 cohort is relatively representative in terms of healthcare-associated infections prevalence across regions, 435 it is not representative of the regional distribution of hospital activity or hospital number in France. 436 Besides, hospitals report their data on a voluntary basis. Consequently, we cannot rule out that there is a 437 selection bias in our cohort. For instance, the observed regional differences in antibiotic consumption and 438 CR-PA incidence may be due to missing university hospitals in some regions. Thirdly, the source of 439 acquisition, i.e. whether bacteria were acquired in the community or in the hospital, was not available. 440 Analyzed data thereby result from dynamics of both settings. Fourth, we did not stratify incidence by 441 specimen type (e.g. bloodstream, genital tract, respiratory tract, skin, body fluids, feces, and urine). We 442 might expect different temporal patterns over the year, notably for lower respiratory tract specimens. 443 Fifth, hospitals only report their antibiotic consumption annually, preventing us from exploring weekly 444 level associations with ABR incidence. Indeed, antibiotic use may display seasonal patterns as observed in 445 the community.<sup>30</sup> Finally, the national surveillance system of ABR changed in 2018, making it impossible 446 to have weekly time series of ABR prior to 2019. Due to this short history, we could not include seasonality 447 in the regression model or account for long-term trends, as previously discussed.

448

In conclusion, hospital antibiotic use and ABR epidemiology strongly varied during the COVID-19 pandemic
 in France. The biological mechanisms underpinning the changes in ABR epidemiology likely vary across
 the investigated antibiotic-bacterium pairs and remain to be elucidated. Continued surveillance efforts in
 hospitals is pivotal and will help build healthcare facilities that are more resilient in pandemic contexts.

- 453
- 454

# 455 **Contributions**

456

ML, LT, LO, and LW designed the statistical analyses. ML, LT, LO, and SK interpreted the results. ML and
DRMS analyzed the data. LS, CD, LD, AJ, SM and LG provided support on data interpretation and analysis.
ML, LT, and LO wrote the manuscript. All authors had access to the processed data and reviewed the
manuscript. All authors take responsibility for the decision to submit for publication.

461

# 462 Acknowledgments

463

464 ML received funding from the National Clinical Research Program and the Investissement d'Avenir 465 program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (ANR-10-LABX-466 62- IBEID). ML thanks the Fondation des Treilles for their support. The authors would like to thank

467 Christian Brun-Buisson for his helpful comments on bacterial sample selection, and Fanny Chéreau for the
 468 very insightful discussions on national surveillance systems collecting hospitalizations of COVID-19
 469 patients.

470

# 471 **Declaration of interests**

472

473 LW reports personal fees from Pfizer, Sanofi and Heva outside the submitted work. LO reports research 474 grants from Pfizer and Sanofi Pasteur through her institution outside the submitted work. The authors

- 475 report no other potential conflicts of interest.
- 476

# 477 Data sharing statement

478

PMSI and SPARES data are not publicly available. R codes to describe antibiotic consumption and quantify
the association between COVID-19-related variables and national or regional resistance data for the
antibiotic-bacterium pairs of interest are available online
(https://github.com/mlayan/abr\_covid\_in\_french\_hospitals).

483

# 484 Ethics approval

485

Because the analysis was performed using anonymized surveillance data, ethical consent was not required
according to the French Data Protection Act. The database was accredited by the French National Data
Protection Commission (CNIL no. 2211022 v 0), and the fully anonymized data waiver for informed
consent of patients was applied.

490

# 491 References

- 492
- Naghavi M, Vollset SE, Ikuta KS, *et al.* Global burden of bacterial antimicrobial resistance 1990–2021: a
   systematic analysis with forecasts to 2050. *The Lancet* 2024; **0**. DOI:10.1016/S0140-6736(24)01867-1.
- Paireau J, Charpignon M-L, Larrieu S, *et al.* Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in France. *BMC Infect Dis* 2023;
  23: 190.
- Bara W, Brun-Buisson C, Coignard B, Watier L. Outpatient Antibiotic Prescriptions in France: Patients
   and Providers Characteristics and Impact of the COVID-19 Pandemic. *Antibiotics* 2022; **11**: 643.
- Weill A, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Zureik M. Usage des médicaments de ville en France durant l'épidémie de la Covid-19 – point de situation jusqu'au 25 avril 2021. Étude pharmacoépidémiologique à partir des données de remboursement du SNDS. EPI-PHARE (Groupement d'intérêt scientifique ANSM-Cnam), 2021 https://www.epi-phare.fr/rapports-detudes-et-publications/covid-19-usage-des-medicaments-rapport-6.
- 505 5 Tomczyk S, Taylor A, Brown A, *et al.* Impact of the COVID-19 pandemic on the surveillance, prevention 506 and control of antimicrobial resistance: a global survey. *J Antimicrob Chemother* 2021; **76**: 3045–58.
- 507 6 Cole J, Barnard E. The impact of the COVID-19 pandemic on healthcare acquired infections with 508 multidrug resistant organisms. *Am J Infect Control* 2021; **49**: 653–4.
- 509 7 Dumartin C, Chabaud A, Couvé-Deacon E, *et al.* Consommation d'antibiotiques et résistances
  510 bactériennes en établissement de santé. Données Spares 2019-2022. *Bull Epidémiologique Hebd* 2023;
  511 : 465–72.
- 512 8 Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review

- and meta-analysis. *Clin Microbiol Infect* 2021; **27**: 520–31.
- 514 9 Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and
   515 meta-analysis. *J Infect* 2020; **81**: 266–75.
- 516 10 Evans ME, Simbartl LA, McCauley BP, *et al.* Active Surveillance and Contact Precautions for Preventing
   517 Methicillin-Resistant Staphylococcus aureus Healthcare-Associated Infections During the COVID-19
   518 Pandemic. *Clin Infect Dis* 2023; **77**: 1381–6.
- 519 11 Smith DRM, Shirreff G, Temime L, Opatowski L. Collateral impacts of pandemic COVID-19 drive the
   520 nosocomial spread of antibiotic resistance: A modelling study. *PLOS Med* 2023; 20: e1004240.
- 12 Cong W, Poudel AN, Alhusein N, Wang H, Yao G, Lambert H. Antimicrobial Use in COVID-19 Patients in
   the First Phase of the SARS-CoV-2 Pandemic: A Scoping Review. *Antibiotics* 2021; **10**: 745.
- 523 13 Cong W, Stuart B, Alhusein N, *et al.* Antibiotic Use and Bacterial Infection in COVID-19 Patients in the
   524 Second Phase of the SARS-CoV-2 Pandemic: A Scoping Review. *Antibiotics* 2022; **11**: 991.
- 14 Hermann B, Benghanem S, Jouan Y, Lafarge A, Beurton A, the ICU French FOXES (Federation Of
  eXtremely Enthusiastic Scientists) Study Group. The positive impact of COVID-19 on critical care: from
  unprecedented challenges to transformative changes, from the perspective of young intensivists. *Ann Intensive Care* 2023; 13: 28.
- 529 15 Langford BJ, Soucy J-PR, Leung V, *et al.* Antibiotic resistance associated with the COVID-19 pandemic:
   a systematic review and meta-analysis. *Clin Microbiol Infect* 2023; **29**: 302–9.
- 16 Pham TM, Zhang Y, Nevers M, *et al.* Trends in infection incidence and antimicrobial resistance in the
  US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22). *Lancet Infect Dis* 2024; published online Aug 13. DOI:10.1016/S1473-3099(24)00416-X.
- 17 WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide
   research, development and strategies to prevent and control antimicrobial resistance.
   https://www.who.int/publications/i/item/9789240093461 (accessed July 9, 2024).
- 18 Cassini A, Högberg LD, Plachouras D, *et al.* Attributable deaths and disability-adjusted life-years caused
  by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a
  population-level modelling analysis. *Lancet Infect Dis* 2019; **19**: 56–66.
- 540 19 Modern Applied Statistics with S, 4th ed. https://www.stats.ox.ac.uk/pub/MASS4/ (accessed July 23, 2024).
- 542 20 Doan T, Worden L, Hinterwirth A, *et al.* Macrolide and Nonmacrolide Resistance with Mass
  543 Azithromycin Distribution. *N Engl J Med* 2020; **383**: 1941–50.
- 544 21 Damonti L, Gasser M, Kronenberg A, Buetti N. Epidemiology of bloodstream infections caused by
  545 extended-spectrum cephalosporin-resistant *Escherichia coli* and *Klebsiella pneumoniae* in Switzerland,
  546 2015–2022: secular trends and association with the COVID-19 pandemic. *J Hosp Infect* 2024; **150**: 145–
  547 52.
- 548 22 Kariyawasam RM, Julien DA, Jelinski DC, *et al.* Antimicrobial resistance (AMR) in COVID-19 patients: a
  549 systematic review and meta-analysis (November 2019–June 2021). *Antimicrob Resist Infect Control*550 2022; **11**: 45.
- Voor in 't holt AF, Severin JA, Lesaffre EMEH, Vos MC. A Systematic Review and Meta-Analyses Show
   that Carbapenem Use and Medical Devices Are the Leading Risk Factors for Carbapenem-Resistant
   Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2014; 58: 2626–37.
- 24 Labaste F, Grossac J, Bounes FV, *et al.* Risk factors for acquisition of carbapenem-resistance during
   treatment with carbapenem in the intensive care unit: a prospective study. *Eur J Clin Microbiol Infect Dis* 2019; **38**: 2077–85.
- 557 25 Ali Brandemeyer O, Dugravot L, Jouzeau A, *et al.* Surveillance de la consommation des antibiotiques et
  558 des résistances bactériennes en établissement de santé. Mission Spares. Résultats synthétiques, année
  559 2022. Saint-Maurice: Santé publique France, 2023.
- 560 26 Mission Spares. Bactéries multirésistantes en établissements de santé en 2018 Mission nationale

- 561 Spares, novembre 2019. Données 2018 du réseau BMR-Raisin. Saint-Maurice: Santé publique France, 562 2019.
- 563 27 Popovich KJ, Aureden K, Ham DC, *et al.* SHEA/IDSA/APIC Practice Recommendation: Strategies to
   564 prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute-care hospitals:
   565 2022 Update. *Infect Control Hosp Epidemiol* 2023; **44**: 1039–67.
- 28 Pichon M, Cremniter J, Burucoa C, *et al.* French national epidemiology of bacterial superinfections in
   ventilator-associated pneumonia in patients infected with COVID-19: the COVAP study. *Ann Clin Microbiol Antimicrob* 2023; 22: 50.
- 29 Lemenand O, Thibaut S, Coëffic T, Caillon J, Birgand G. Resistance to third-generation cephalosporins,
   carbapenems and fluoroquinolones in Escherichia coli urinary isolates in primary care: trends in France
   2017–2021. Bull Épidémiol Hebd 2023; 22–23: 458–64.
- 30 Sun DS, Kissler SM, Kanjilal S, Olesen SW, Lipsitch M, Grad YH. Analysis of multiple bacterial species and
   antibiotic classes reveals large variation in the association between seasonal antibiotic use and
   resistance. *PLOS Biol* 2022; **20**: e3001579.



609 610

Figure 1. Data sources and selection. (A) Hospitals report their antibiotic resistance data in SPARES using either
their geographical identifier or their legal identifier, the latter generally grouping multiple geographical entities. We
excluded all hospitals that use their legal identifier, except for teaching hospitals that often host the most severe cases.
For teaching hospitals that report their data under their legal identifier, we retrieved occupied bed-days data from the
PMSI using the geographical identifiers of all relevant entities (see appendix pp 3-6 for more details). (B) Flow
diagram of sample selection. We focused our investigations on meticillin-resistant *S. aureus*, ESBL-producing *E. coli*, *K. pneumoniae*, and *E. cloacae* complex, and carbapenem-resistant *P. aeruginosa. E. cloacae* complex include

617 Enterobacter cloacae, Enterobacter absuriae, Enterobacter hormaechei, Enterobacter kobei, Enterobacter ludwigii, 618 and Enterobacter nimipressuralis. Among the duplicated samples with different phenotypes, we excluded the least 619 resistant phenotypes, meaning phenotypes S if R or I, and phenotypes I if R (2,219/4,442, 50%). In total, we selected 620 34% of isolates from the global database and 36% of samples isolated in intensive care units (ICUs). (C) Flow diagram 621 of hospitals and ICUs selection. Hospitals located in French overseas territories and Corsica were removed due to 622 specific epidemiological situations as well as low numbers that would decrease the statistical power of the regional 623 analyses. (D) Geographical distribution of hospitals and ICUs across the 12 regions of mainland France.

624 GPH: general public hospital; PPH: private for profit hospital; PNPH: private not-for-profit hospital; RH: 625 rehabilitation hospital; UH: university hospital.



Figure 2. Regional heterogeneity in antibiotic consumption in French hospitals, 2019-2022. (A) Changes of
 antibiotic consumption across French regions between 2019 and 2020. Colors indicate the median percentage change
 of antibiotic consumption between 2019 and 2020. We excluded hospitals reporting no consumption in 2019 to
 calculate this metric. Dark blue colors indicate increased consumption and dark orange colors indicate decreased
 consumption. We also performed paired Wilcoxon signed-rank tests to compare regional distributions of antibiotic

- 673 consumption in 2019 and 2020. Circle size indicates the level of significance of the paired Wilcoxon signed-rank tests
- 674 when the p-value is  $\leq 0.05$ . (B) Dynamics of azithromycin consumption across French regions during the study period.
- 675 Each panel represents a French region whose geographical location is shown on the right. Gray lines correspond to
- 676 the trajectories of individual hospitals and colored circles to the average regional antibiotic consumption in defined
- daily doses (DDD) for 1,000 occupied bed-days. Colors indicate the level of significance of the Friedman test which
- 678 is the non-parametric equivalent of one-way repeated measures ANOVA tests. We also indicate the corrected p-values
- of the paired Wilcoxon signed-rank tests between 2019 and the other years of the study period when corrected pvalues are  $\leq 0.05$ . We used a Bonferroni correction.
- 681 n.s. : p-value>0.05; \*: p-value<0.05; \*\*: p-value<0.01; \*\*\*: p-value<0.001.
- 682 ARA: Auvergne-Rhône-Alpes; BFC: Bourgogne-Franche-Comté; BRE: Bretagne; CVL: Centre-Val de Loire; GES:
- 683 Grand-Est; HDF: Hauts-de-France; IDF: Île-de-France; NAQ: Nouvelle-Aquitaine; NOR: Normandie; OCC:
  684 Occitanie; PAC: Provence-Alpes-Côte d'Azur; PDL: Pays de la Loire.



**Figure 3.** Antibiotic resistance in hospitals in France, 2019-2022. (A) Annual number of samples isolated in our hospital cohort (*n*=414 hospitals) between 2019 and 2022 and stratified by bacterial species. (B) Annual proportion of resistant bacterial isolates from 2019 to 2022 in our hospital cohort. Intervals indicate the 95% Wilson CIs. (C) Temporal trend of resistance proportions between 2019 and 2022. Stars indicate the level of significance of the  $\chi^2$ trend test for proportions. (D) Weekly incidence of resistant infections for 1,000 bed-days over the study period in hospitals and intensive care units (ICUs). The strips indicate the level of anti-COVID-19 interventions in the community.<sup>2</sup>

737 \*: p-value≤0.05; \*\*: p-value≤0.01; \*\*\*: p-value≤0.001.

ESBL E. cloacae: ESBL-producing *Enterobacter cloacae* complex; ESBL E. coli: ESBL-producing *Escherichia coli*;
 ESBL K. pneumoniae: ESBL-producing *Klebsiella pneumoniae*; CR P. aeruginosa: carbapenem-resistant
 *Pseudomonas aeruginosa*; MRSA: methicillin-resistant *Staphylococcus aureus*.



760 761 not include COVID-19-related variables, thus they do not appear on the forest plots. For the other cases, the best 762 models included either the COVID-19-related periods at week w, or the COVID-19 intubation prevalence at week w-763 2. IRR estimates for the COVID-19-related periods are relative to the pre-pandemic period. (B) IRRs of best regression 764 models for the autocorrelation term and antibiotic consumption. Here, "target antibiotic" refers to the antibiotic class 765 targeted by the resistance of the pathogen considered, namely broad-spectrum penicillins for ESBL-producing 766 Enterobacterales, imipenem+meropenem for CR-PA, and narrow spectrum penicillins for MRSA. (C) IRRs by 767 administrative region using the best model selected at the national level on carbapenem-resistant P. aeruginosa (CR-768 PA) isolate incidence including the prevalence of COVID-19 intubated patients. (D) IRRs by administrative region

757 758

- vising the best model at the national level on ESBL-producing *E. coli* (ESBL *E. coli*) and methicillin-resistant *S. aureus*
- (MRSA) isolate incidence including the pandemic periods at week w. Shaded IRRs have a p-value > 0.05. Intervals
- correspond to the 95% CIs of the point estimates. (E) Annual prevalence of intubated COVID-19 patients for 1,000
   bed-days by region. Île-de-France (IDF), Grand-Est (GES), Provence-Alpes-Côte d'Azur (PAC), and Auvergne-
- 773 Rhône-Alpes (ARA) were the most affected regions during the first two years of the pandemic.
- 774 ESBL E. cloacae: ESBL-producing *Enterobacter cloacae* complex; ESBL E. coli: ESBL-producing *Escherichia coli*;
- ESBL E. cloacae: ESBL-producing *Enterobacter cloacae* complex; ESBL E. con: ESBL-producing *Escherichia coli*;
   ESBL K. pneumoniae: ESBL-producing *Klebsiella pneumoniae*; CR P. aeruginosa: carbapenem-resistant
   *Pseudomonas aeruginosa*; MRSA: methicillin-resistant *Staphylococcus aureus*.
- 777 ARA: Auvergne-Rhône-Alpes; BFC: Bourgogne-Franche-Comté; BRE: Bretagne; CVL: Centre-Val de Loire; GES:
- 778 Grand-Est; HDF: Hauts-de-France; IDF: Île-de-France; NAQ: Nouvelle-Aquitaine; NOR: Normandie; OCC:

- 779 Occitanie; PAC: Provence-Alpes-Côte d'Azur; PDL: Pays de la Loire.

		Friedma n test p- value	2019 vs 2020		2019 vs 2021		2019 vs 2022	
			Estimate (98·3% CI)	p-value <sup>1</sup>	Estimate (98·3% CI)	p-value <sup>1</sup>	Estimate (98·3% CI)	p- value <sup>1</sup>
Aminoglycosid		<0.001	0	1	-0.3	0.004	-0.7	<0.001
es			(-0.2, 0.2)		(-0.6, -0.1)		(-1.0, -0.4)	
Carbapenems		<0.001	0.6	<0.001	0.4	<0.001	0.2	0.288
			(0.3, 0.8)		(0.2, 0.8)		(-0.1, 0.5)	
	Imipenem +	<0.001	0.2	<0.001	0.4	<0.001	0.2	0.139
	Meropenem		(0.2, 0.7)		(0.2, 0.7)		(0, 0.5)	
Cephalosporins		<0.001	3.7	<0.001	3.4	<0.001	2.6	<0.001
			(2.5, 5.2)		(2.0, 4.9)		(0.9, 4.4)	
Fosfomycin		<0.001	0.2	<0.001	0.3	<0.001	0.4	<0.001
			(0.1, 0.3)		(0.2, 0.4)		(0.3, 0.5)	
Glycopeptides		<0.001	0.1	0.864	-0.3	0.014	-1.0	<0.001
			(-0.1, 0.4)		(-0.6, 0)		(-1·4, -0·6)	
	Vancomyci	<0.001	0.1	0.348	-0.2	0.074	-0.8	<0.001
	n		(-0.1, 0.3)		(-0.4, 0)		(-1·1, -0·5)	
Lipopeptides		<0.001	1.6	<0.001	2.4	<0.001	4.3	<0.001
			(1.1, 2.1)		(1.8, 3.2)		(3·3, 5·5)	
Macrolides		<0.001	1.7	<0.001	-0.5	0.609	-0.8	0.062
			(0.9, 2.6)		(-1.3, 0.4)		(-1.7, 0)	
	Azithromyci	<0.001	1.3	<0.001	0.6	<0.001	0.2	<0.001
	n		(1.0, 1.7)		(0.4, 0.8)		(0.3, 0.8)	
Monobactams		<0.001	0.1	<0.001	0.2	<0.001	0.5	<0.001
			(0, 0.2)		(0.1, 0.3)		(0.1, 0.3)	
Oxazolidinone		<0.001	0.4	<0.001	0.4	<0.001	0.7	<0.001
S			(0.2, 0.6)		(0.2, 0.6)		(0.4, 0.9)	
Penicillins		<0.001	-2.5	0.075	-6·4	<0.001	-0.8	1
			(-5.2, 0.2)		(-9·3, -3·4)		(-4.2, 2.5)	
Polymyxins		0.002	0.1	<0.001	0.2	<0.001	0	0.816
			(0.1, 0.2)		(0.1, 0.3)		(0, 0.1)	
Quinolones		<0.001	0.2	1	-1.3	0.068	-1.6	0.030
			(-0.9, 1.4)		(-2.7, 0.1)		(-3.0, -0.1)	
Tetracyclines		0.002	0.3	0.214	0.4	0.057	0.2	0.040
			(-0.1, 0.7)		(0, 0.8)		(0, 0.9)	
Trimethoprim <sup>2</sup>		0.001	0.4	0.031	0.4	0.146	0.7	0.003
			(0, 0.9)		(-0.1, 0.9)		(0.2, 1.2)	
Total		0.001	7.5	<0.001	-0.3	1	5.3	0.107
			(2.7, 12.5)		(-5.9, 5.3)		(-0.8, 11.4)	

<sup>1</sup>Adjusted p-value with Bonferroni correction

<sup>2</sup>Corresponds to trimethoprim and combinations of sulfanomides

818

819 Table 1. Changes in annual antibiotic consumption in French hospitals, 2019-2022. We report absolute 820 differences in consumption at the hospital level for every antibiotic class, as well as imipenem and meropenem, 821 vancomycin, and azithromycin specifically. Estimates correspond to the median of the differences of antibiotic 822 consumption (in DDD per 1,000 bed-days) between two years of the study period, using 2019 as a reference year.

823 824 825 826 827	Positive values thereby indicate an increased consumption compared to 2019 and negative values indicate a reduced consumption compared to 2019. For every pairwise comparison, we report the adjusted p-value of the paired Wilcoxon signed-rank test using a Bonferroni correction and the associated $98 \cdot 3\%$ CI. Finally, we report Friedman tests p-values that are the non-parametric equivalent of one-way repeated measures ANOVA tests to evaluate whether there are changes in antibiotic use over the study period.
828	6 71
829	
830	
831	
832	
833	
834	
835	
836	
837	
838	
839	
840	
841 040	
04Z	
043 011	
044 815	
845 846	
847	
848	
849	
850	
851	
852	
853	
854	
855	
856	
857	
858	
859	
860	
861	
862	
863	
864	
865	
866	
867 868	
000 000	
009 070	
070	

		Friedman test p- value	2019 vs 2020		2019 vs 2021		2019 vs 2022	
			Estimate	p- value <sup>1</sup>	Estimate (98·3% CI)	p- value <sup>1</sup>	Estimate (98·3% CI)	p-value <sup>1</sup>
			(98·3% CI)					
Aminoglycosid		0.001	-4.0	0.639	-5.4	0.636	-11.3	0.004
es			(-11.1, 3.4)		(-15.2, 5.1)		(-19·3, -3·0)	
Carbapenems		<0.001	12.2	0.001	14.4	0.004	10.1	0.078
			(4·1, 19·4)		(4.5, 23.8)		(-0.9, 20.1)	
	Imipenem +	<0.001	12.5	<0.001	15.8	<0.001	12.5	0.018
	Meropenem		(4.7, 19.8)		(6.7, 25.1)		(1.9, 22.4)	
Cephalosporins		0.011	24.5	<0.001	19.4	0.042	25.5	0.003
			(8.2, 38.9)		(0.5, 37.6)		(6.8, 44.4)	
Fosfomycin		0.351	0	1	0	1	-0.3	0.223
			(-0.6, 0.5)		(-0.6, 0.4)		(-0.9, 0.1)	
Glycopeptides		0.002	1.1	1	-5	0.13	-4.7	0.106
			(-4, 5.3)		(-10.6, 0.9)		(-10.8, 0.7)	
	Vancomyci	0.002	0.7	1	-4.3	0.166	-4.6	0.115
	n		(-3.9, 5.1)		(-9.9, 1.1)		(-10.7, 0.8)	
Lipopeptides		<0.001	8.8	0.004	7.1	0.033	16.9	<0.001
			(2·4, 15·1)		(0.4, 14.1)		(10.2, 24.2)	
Macrolides		<0.001	17.4	<0.001	-4.2	0.942	-5.6	0.447
			(7.7, 28.9)		(-14.0, 6.5)		(-14.8, 3.9)	
	Azithromyci	<0.001	12.7	<0.001	0.8	0.459	1.1	0.146
	n		(5.8, 20.5)		(-0.5, 2.7)		(-0.3, 2.7)	
Monobactams		0.008	1.0	0.04	1.3	0.059	1.3	0.003
			(0, 2.3)		(0, 3.0)		(0.4, 2.2)	
Oxazolidinones		0.048	2.3	0.654	0.5	1	4.1	0.163
			(-2.3, 7.3)		(-4.6, 6.2)		(-1.1, 8.7)	
Penicillins		<0.001	-51.2	<0.001	-69.1	<0.001	-10.1	1
			(-78.0, -27.1)		(-98.1, -39.9)		(-40.6, 19.6)	
Polymyxins		0.009	1.3	0.043	2.3	0.003	0.3	1
			(0, 2.7)		(0.7, 4.7)		(-0.6, 1.6)	
Quinolones		0.003	-14·9	<0.001	-12.7	0.024	-14·3	0.007
			(-24·4, -5·7)		(-24·4, -1·6)		(-26.5, -3.5)	
Tetracyclines		0.619	-0.1	1	-0.1	1	0.9	0.987
			(-2.4, 1.9)		(-2.8, 2.4)		(-1.5, 3.6)	
Trimethoprim <sup>2</sup>		0.065	-1.7	1	0.1	1	5.9	0.017
			(-6·4, 3·1)		(-5.7, 5.6)		(0.9, 11.9)	
Total		0.028	4.1	1	-41.0	0.456	24.1	0.780
			(-40.9, 49.4)		(-105.5, 24.3)		(-29.7, 80.9)	

<sup>1</sup>Adjusted p-value with Bonferroni correction

<sup>2</sup>Corresponds to trimethoprim and combinations of sulfanomides

871

872 Table 2. Changes in annual antibiotic consumption in French ICUs, 2019-2022. We report absolute differences
873 in consumption at the ICU level for every antibiotic class, as well as imipenem and meropenem, vancomycin, and
874 azithromycin specifically. Estimates correspond to the median of the differences of antibiotic consumption (in DDD
875 per 1,000 bed-days) between two years of the study period, using 2019 as a reference year. Positive values thereby

876 indicate an increased consumption compared to 2019 and negative values indicate a reduced consumption compared

to 2019. For every pairwise comparison, we report the adjusted p-value of the paired Wilcoxon signed-rank test using
a Bonferroni correction and the associated 98.3% CI. Finally, we report Friedman tests p-values that are the non-

a Bonferroni correction and the associated 98.3% CI. Finally, we report Friedman tests p-values that are the non parametric equivalent of one-way repeated measures ANOVA tests to evaluate whether there are changes in antibiotic

880 use over the study period.